Rationale-Our prior RNA sequencing study found that FAM13B gene expression in human left atrial appendages was strongly associated with an atrial fibrillation (AF) susceptibilityassociated variant on chr. 5q31.
Atrial fibrillation (AF) is the most common human arrhythmia and has a strong heritable component. 1 The most recent genome wide association studies (GWAS) for AF susceptibility identified ~100 loci associated with AF. 2, 3 . However, further work on each locus is necessary to identify the causal gene, the causal genetic variant, and the mechanism for association with AF. Since most AF GWAS SNPs, or those in strong linkage disequilibrium with them, do not alter the protein amino acid sequence, we hypothesize that most of these GWAS loci are regulatory, leading to changes in gene expression rather than protein structure. Our prior expression quantitative trait locus (eQTL) study utilized next generation RNA sequencing (RNAseq) and single nucleotide polymorphism (SNP) genotyping in human left atrial appendages to identify the cis genes whose expression are associated with the top SNP at the AF GWAS loci. 4 We identified FAM13B as the gene whose expression is associated with the top GWAS SNP at chr. 5q31. Here, we describe how an eQTL analysis in a small African descent cohort led to the identification of a candidate SNP, rs17171731, in the chr. 5q31 AF GWAS locus that controls FAM13B gene expression. We validated this candidate SNP through reporter gene transfections, gel mobility shift assays, and gene editing in human pluripotent stem cells. Thus, the chr. 5q31 GWAS locus appears to be mediated by regulating the expression of FAM13B, a poorly characterized member of the rho GTP activating domain gene family. 5, 6 We then used siRNA to knockdown FAM13B in stem cell-derived cardiomyocytes in order to investigate the mechanism by which decreased FAM13B gene expression leads to increased AF risk. Knockdown of FAM13B expression altered the expression of >1000 cardiomyocyte genes, including a subunit of the voltage-dependent sodium channel, which suggests possible mechanisms by which the genetic regulation of FAM13B could result in AF susceptibility. Expression of GFP-tagged FAM13B in stem cell derived cardiomyocytes s localized FAM13B protein to the plasma membrane and Z-disk.
Methods

Human Left Atrial Tissue Samples and Processing
Human left atrial appendage tissues were obtained from patients undergoing elective surgery to treat AF, valve disease, or other cardiac disorders. LA tissue specimens were also obtained from non-failing donor hearts not used for transplant. Demographics of this population were previously published. 4 Total RNA was isolated for subsequent sequencing analysis. These methods are detailed in our prior publication. 4
Genomic DNA isolation and SNP microarray As previously described 4 , genomic DNA was genotyped using Illumina Hap550v3 and Hap610quad SNP microarrays. In order to derive genotypes in addition to those on the microarray, the SNP data was imputed to 1000 Genomes Project phase 2 to generate genotypes for ~19 million SNPs, using the IMPUTE software. 7
RNA isolation, sequencing, and analysis
As previously described 4 , 100-bp paired-end sequencing was performed on the Illumina HiSeq 2000 platform and multiplexed to 6 samples across two lanes. The sequence reads were mapped to the human genome to derive a digital count of the expression of genes, which were defined using the Ensembl gene catalog (version 71). Reads were quantile normalized, and gene counts for eQTL analysis were variance-stabilized transformed as previously described. 4 eQTL analyses were performed separately for each racial group with beta-coefficients calculated as the additive effect of one allelic difference on log2 gene expression. Genetic multidimensional scaling (MDS) from SNP array genotyping were additionally calculated and added as covariates for the eQTL calculation. matrixeQTL 8 was used to test associations between genotype and variance stabilized counts. The qvalue package was used to calculate false discovery rate (FDR) from the complete list of p values. 9
Human stem cell culture and cardiac differentiation H9 human embryonic stem cells (WiCell) were cultured in TesR-E8 media (STEMCELL 05990) on plates coated with growth factor-reduced Matrigel (ThermoFisher CB-40230). After passaging, H9 cells were cultured in the presence of 10 M Y-27632 (Abcam) for 24-48 hours. Cardiac differentiation of H9 cells was conducted using the STEMdiff Cardiomyocyte Differentiation Kit (STEMCEll 05010).
Reporter gene expression analysis
26-mer oligonucleotides (Table 1) containing the FAM13B SNP rs17171731 reference or risk allele sequences were cloned into the luciferase reporter pT81luc. 10 The luciferase reporter and the β-galactosidase expression vector pCH110 were transfected into H9 human embryonic stem cell-derived cardiomyocytes via electroporation (Nucleofector-II program A-23, Lonza VPH-5012). Cell lysates were prepared and analyzed for β-galactosidase and luciferase activities using the Dual Light Reporter Gene Assay system (ThermoFisher T1003).
FAM13B electrophoretic mobility shift assays
26-mer oligonucleotides containing the rs17171731 reference or risk allele sequences (Table 1) were labeled with γ-32 P-ATP (10 μCi/μL) using T4 polynucleotide kinase (NEB M0201) and annealed with complementary oligonucleotides in 10 mM Tris, 1 mM EDTA, 50 mM NaCl. The resulting probes were combined on ice with human heart nuclear extract (Active Motif 36041), 1.25 μg poly(dI dC) (Sigma-Aldrich P4929) and reaction buffer (final concentration 45 mM KCl, 1 mM MgCl2, 15 mM HEPES pH 7.9, 1 mM DTT, 3% Ficoll 400) in the presence or absence of unlabeled competitor oligonucleotides, then incubated at room temperature for 25 minutes before running on Novex 6% DNA Retardation gels (ThermoFisher EC63655BOX). Dried Gels were exposed to X-ray film. We attempted to identify proteins bound to the probes using the following antibodies: ABI3, ATF4, MTF-1, POU2F1, POU2F2, SOX4, and SOX8 (One World Lab), as well as ZNF143 (R&D Systems).
IPSC-derived cardiomyocyte culture and siRNA knockdown of FAM13B
Cardiomyocytes derived from human inducible pluripotent stem cells (iPSCs) (iCell cardiomyocytes, Cellular Dynamics International, Madison, WI) were cultured and siRNA knockdown was performed using Cellular Dynamics International protocols. In short, 1.5 x 10 5 cells were plated per well in fibronectin (Sigma)-coated 12-well plates. The cells were cultured in iCell cardiomyocyte maintenance media (Cellular Dynamics Int.) for seven days; beating was observed at about day six. Final concentrations of 50 nM/well of control scramble siRNA (Thermo-Fisher/Ambion silencer select cat#4390843) or FAM13B siRNA (Thermo-Fisher/Ambion cat# 439242, id S27906) were transfected into iCell cardiomyocytes using the TransIT-TKO transfection reagent (Mirus Bio). The cells were incubated with the siRNA-reagent complexes for 48-96 hours followed by either cellular electrophysiology studies or total RNA isolation, cDNA preparation, qRT-PCR, and RNAseq (described above).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
Total RNA was isolated from the iCell cardiomyocytes after siRNA knockdown using the Cellular Dynamics International protocol (Total RNA protocol) and the RNeasy Micro Kit (Qiagen) with the following modification: from step 3 through 5, the reagent volumes were doubled to accommodate the increased well size. 100-250 μg of RNA was reverse transcribed using SuperScript IV VILO™ Master Mix (Thermo-Fisher/Invitrogen). 12.5 μl of the TaqMan® gene expression master mix (Applied Biosystems), 1.25 μl of FAM-labeled FAM13B primer/probe mix (assay number HS00991421_M1, Thermo-Fisher), and 1.25 μl VIC-labeled primer limited cardiac actin (ACTC1) primer/probe mix (assay number Hs00606316_m1, Thermo-Fisher) were mixed to create a master mix to be added to each sample. 15 μl aliquots of master mix were dispensed into individual wells of a 96-well working plate along with 10 μl of undiluted cDNA. A 5 μl aliquot of this working mixture was pipetted in triplicate to a 384-well assay plate using an epMotion (Eppendorf model 5070) automated pipetting robot. Real time PCR was performed using a Bio-RAD CRX thermocycler that is calibrated for FAM and VIC fluorescent probes. Thermal cycling was performed with a hot-start at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. The ΔC(t) values for FAM13B expression levels were calculated relative to ACTC1. ΔΔC(t) values were used to calculate the decrease of FAM13B expression and the results were converted to base 10 values by calculating 2 -ΔΔC(t) .
Cellular electrophysiology methods
Patch clamp studies of FAM13B knockdown cells focused on measurement of sodium currents (INa) in scramble and FAM13B-siRNA treated iCell cardiomyocytes. Cells were replated at low density 24 hours after siRNA treatment (non-touching), and electrophysiology studies were performed 48 to 96 hours after transfection. Sodium currents were recorded at room temperature using whole cell clamp techniques. Pipettes (Corning 8161 thin-walled glass, 1.5-3 M) were filled with a solution containing 135 mM CsCl2, 10 mM NaCl, 2 mM CaCl2, 5 mM EGTA, 10 mM HEPES, 5 mM MgATP, and titrated to pH 7.2 with CsOH. The cells were continuously superfused with an extracellular solution containing: 50 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2, 110 mM CsCl, 10 mM glucose, 10 mM HEPES, 1 M nifedipine (added fresh daily), pH 7.4. Currents were recorded with an Axopatch 1C amplifier controlled with pClamp 8.1 software (Molecular Devices). After seal formation and patch rupture, whole cell access resistance was 2-5 M. To maintain cell viability, resting potential was held at -60 mV, with more negative steps given 100 ms before depolarizing steps used to record sodium currents. Voltage clamp protocols are shown in Figure 4 A,C,F. Current amplitudes recorded with the steady-state inactivation protocol (Figures 4C,D) were fit with a Boltzmann curve in Clampfit 8.1 (pClamp, Molecular Devices). To avoid time-dependent changes in siRNA exposure, data were obtained from similar numbers of scramble and siRNA-treated cells on each day. Data are reported as mean  standard error of the mean. All electrophysiologic comparisons between scramble and FAM13B-siRNA treated cells were evaluated using a 2 tailed T-test or a 2-way ANOVA as indicated.
Analysis of FAM13B-GFP expression
The FAM13B-EGFP fusion protein expression vector was constructed by VectorBuilder Inc (#VB190426-1100mup). The elongation factor 1α short (EFS) promoter drives the expression of the human FAM13B coding sequence[NM_016603.3] fused at its C-terminus to the eGFP coding sequence, with a Neomycin resistance gene inserted downstream of FAM13B-EGFP sequence connected by T2A Linker.. iCell Cardiomyocytes (Cellular Dynamics) were plated at a density of 5x 10 4 cells per well into 0.1% Gelatin treated glass-bottom 96-well plate according to the manufacturer's instruction. The cells were maintained in iCell Cardiomyocytes Maintenance medium. 48 hours later, the cells were transfected with EFS-FAM13B-EGFP plasmid using ViaFect transfection Reagent (Promega Corporation) at a 4:1 reagent-to-DNA ratio (vol:wt) and 0.1 µg plasmid DNA per well. Four to six days later, the cardiomyocytes were fixed with 10% Neutral Buffered Formalin for 10 min at room temperature. After incubation with 0.1% Triton X 100 for 20min to permeabilize the cell membrane, the cells were washed and incubated with Casein Blocker (Thermo Fisher Scientific) for 1 hour at room temperature. The cells were incubated with mouse anti α-actinin primary antibody (1:500 dilution, #A7811, Sigma Aldrich) at 4°C overnight, and then with Alexa Fluor 568 labeled goat anti-mouse IgG secondary antibody (1:500 dilution, #A11004, Thermo Fisher Scientific) for 2 hours at room temperature. Nuclei were counterstained with Hoechst 33342 for 5min and epifluorescent micrographs were obtained.
Data Access
Variance normalized gene expression levels for each subject are available in the GEO database, accession number GSE69890. LAA eQTL data can be obtained on our web browser: http://afeqtl.lerner.ccf.org/.
Results
African descent eQTL analysis for FAM13B gene expression
Our published left atrial appendage RNAseq-eQTL analysis focused on 235 subjects with selfreported European ancestry as well as 30 African American subjects whose ancestry was verified by SNP array principal component analysis, to be admixed or clustered closely with African reference samples. 4 In the European ancestry subjects, we showed that the GWAS SNP at the chr. 5q31 locus, rs2040862, was a strong eQTL for expression of the FAM13B gene (p = 7x10 -30 ). However, this SNP is in strong linkage disequilibrium (LD) with many other SNPs that have similar eQTL p-values. 4 Although our African American cohort was small, we were able to detect a significant eQTL for FAM13B expression. The rs17171731 SNP, located ~20 kb upstream of the FAM13B transcription start site, stood out with an eQTL p-value ~10-fold stronger than the other SNPs in this region ( Figure 1A, B ; p = 2.63x10 -5 ). rs17171731 is in high LD with the GWAS SNP in our European ancestry subjects (r 2 = 0.96). Note, rs17171731 is not included in the 1000 Genomes phase 3 database, but it was present in the phase 1 database used for imputation.
Functional studies of the FAM13B candidate causal SNP
Based on the cis-eQTL analysis (Figure 1A, B ) and DNaseI hypersensitivity in human fetal heart ( Figure 1C ), we identified rs17171731 as the top candidate causal SNP regulating FAM13B gene expression. In order to detect enhancer activity in this region, we subcloned 26-mer oligos containing the reference or risk alleles of rs17171731 (Table 1 ) into a luciferase reporter plasmid driven by a minimal viral thymidine kinase (TK) promoter (pT81luc). After transfection into cardiomyocytes differentiated from H9 embryonic stem cells, we observed that the risk allele had weak enhancer activity, and the reference allele had 3.3-fold stronger activity vs. the risk allele (p<0.001, Figure 2A ).
We then performed electromobility shift assays using 32 P-labeled 26mer oligos surrounding the rs17171731 SNP ( Figure 2B ). Incubation of the reference allele probe with human heart nuclear extract yielded one strongly shifted fragment (Band 1), while the risk allele yielded both Band 1 and a smaller shifted fragment (Band 2). Band 1 was effectively competed off of both probes with excess unlabeled reference or risk oligos; however, Band 2 was competed off more effectively with the risk vs. reference oligo. Using a different lot of heart nuclear extract that had more prominent Band 2 vs. Band 1 shifts, along with the risk allele probe, we performed competition studies using nine unlabeled oligos (Table 1) with single bp changes extending ±4 bp from the rs17171731 SNP site ( Figure 2C ). We determined that the central sequence motif required for the Band 2 shift was TGCA, with the rs17171731 risk allele representing the C of this motif. We searched the JASPAR transcription factor motif database 11 for TGCA binding factors with scores >93.5 and narrowed our list to those that were expressed in LA based on our RNAseq data 4 , which yielded the following eight factors: ATF4, POU2F1, SOX4, ZNF143, SOX8, ABI3, MTF1, and POU2F2. Commercially available antibodies against these proteins did not supershift or block Band 2 formation (data not shown); thus, we did not identify the heart nuclear protein(s) responsible for the Band 2 shift, which presumably mediate the silencing activity of the rs17171731 risk allele.
FAM13B (prior gene name C5ORF5 5 ) is a member of the Rho-GAP gene family. In silico analysis of the FAM13B Rho-GAP domain indicates that two highly conserved putative GTPase catalytic residues are altered in the FAM13B protein, potentially yielding a non-catalytic protein. 5 To begin to evaluate the mechanism whereby FAM13B impacts atrial arrhythmogenesis, RNAseq and patch clamp studies were performed to assess the effect of FAM13B siRNA-transfection vs. a scrambled siRNA on cardiomyocytes derived from iPSCs. Four days after FAM13B siRNA transfection, we observed 77% knockdown of FAM13B mRNA expression by qPCR ( Figure 3A) . RNAseq analysis of the FAM13B and scrambled siRNA treated cells revealed that expression of 1156 genes was significantly altered after FAM13B knockdown (FDR adjusted p<0.1, n=3 per condition, Supplemental Table 1) , and the top 20 most significant changes in gene expression are shown in Table 2 . While expression levels of prominent atrial ion channel pore subunits were not significantly impacted by FAM13B knockdown, expression of SCN2B, which encodes a beta-subunit of the cardiac sodium channel, was the 11 th strongest regulated transcript, and it was down regulated 2.2-fold by FAM13B knockdown ( Table 2) . Ingenuity Pathway analysis revealed that SCN2B was a member of the second strongest empirical network associated with FAM13B knockdown ( Figure 3B ).
Patch clamp studies of FAM13B knockdown cells focused on measurement of sodium current (INa) density ( Figure 4A,B) , steady state inactivation (Figure 4C ,D) and late sodium current (INaL, Figure 4E ,F). FAM13B knockdown induced loss of SCN2B did not significantly impact the peak sodium current density ( Figure 4B) . FAM13B knockdown increased the V1/2 for the steady state inactivation of the INa by 2.7 mV ( Figure 4D ), and although this effect did not reach p<0.05 by ttest, a 2-way ANOVA test showed a significant difference between the curves (p=0.002 for interaction between treatment and voltage). Cell capacitance was not significantly different between groups (KD: 39.56.5 pF vs. SCR 36.44.5 pF). Late sodium current density (INaL) was evaluated using a ramp clamp protocol ( Figure 4E ). There was a tendency for INaL density to be larger in the FAM13B knockdown cells compared to the scramble (-1.730.33 vs. -1.240.13 pA/pF, p=0.20). When subdivided by cell capacitance above and below the median value (37.7 pF), the difference in INaL density between knockdown and scramble groups was significant for the smaller capacitance cells (p=0.0443), but not for the larger capacitance cells (p=0.879). The ratio of INaL/peak INa was significantly increased in the FAM13B knockdown cells, regardless of cell capacitance (Figure 4F, p=0.025 ).
To gain more insight into FAM13B mechanism of action, we transfected different cell types with a FAM13B-GFP fusion protein construct. Upon transfection into non-cardiomyocyte HEK293 and human iPS cells, we observed a few GFP+ cells two days after transfection, but these cells were compact, round, and poorly attached, and had died by day four, such that no GFP+ cells remained on the dish. However, after transfection into iCell cardiomyocytes, we observed robust GFP+ staining on the plasma membrane and in sarcomeres ( Figure 5 ). We used antibodies directed to the Z-disc (-actinin), the sarcoplasmic reticulum (serca2) and we observed the better co-localization with -actinin ( Figure 5 ).
Discussion
In our prior LAA RNAseq analysis, the second strongest AF GWAS SNP eQTL was for FAM13B at a locus previously attributed to WNT8A. 4 At this locus, the minor allele of rs2040862 is the AF risk allele, and this allele is associated with decreased expression of FAM13B. The FAM13B gene encodes an uncharacterized protein containing a Rho GTPase activation protein (RhoGAP) domain. 5 The eQTL plots for LAA FAM13B expression in European and African American descent subjects and a DNaseI hypersensitivity peak map in fetal heart tissue allowed us to identify rs17171731 as a top candidate functional SNP. Our reporter gene transfection into iPS derived cardiomyocytes show that rs17171731 is a causal variant, with the risk allele having decreased enhancer activity, in the same direction as observed in human LAA tissue. A different SNP at chr. 5q31 (rs1004989) that was previously associated with the electrocardiographic QTinterval was found to be a significant eQTL for FAM13B expression in left ventricle tissue samples 12 ; however, rs1004989 is not in LD with the best left atrial FAM13B eQTL SNP (rs17171731), perhaps illuminating tissue-specific regulatory variants controlling FAM13B gene expression.
To begin to assess the functional role of FAM13B, we used siRNA knockdown in human cardiomyocytes differentiated from iPSCs. RNAseq analysis of the siRNA knockdown cells showed a striking pattern with extensive co-regulation with more than 1000 other genes, suggesting the FAM13B may be a hub gene that plays a role in regulating LA physiology. Pathway analysis found a strong empirical network that included SCN2B, a subunit of the cardiac sodium channel, which we identified as one of the most down-regulated genes. In ventricular cardiomyocytes from normal and heart failure dogs, virally delivered siRNA knockdown of SCN2B was associated with increased late sodium current (INaL). 13 INaL, resulting from either genetic or environmental influences, has been associated with action potential prolongation in heart failure, and both INaL 14 and mutations in SCN2B have been associated with risk of AF. 15 Results of our electrophysiology studies in the FAM13B knock-down iPSC-derived cardiomyocytes were similar to the effects of SCN2B knockdown in canine ventricular cardiomyocytes. 13 We noted trends toward a positive shift in the steady state inactivation of the sodium current ( Figure 4D) and an increased density of the slowly inactivating sodium current ( Figure 4E ), resulting in a significantly increased fraction of INaL/peak INa ( Figure 4F ). In our study, peak INa was not different between groups ( Figure 4B ), but INaL was increased in smaller (likely atrial and nodal) cells to a greater extent than in the larger capacitance cells. Sodium currents are not identical in atrial and ventricular cardiomyocytes, likely due to differences in sodium channel subunit composition and cellular architecture.
The determinants of peak and late sodium current density are complex, with roles for channel trafficking, CaMKII phosphorylation, subunit interactions, oxidative stress and metabolic status suggested as potential modifiers. We suggest that increased INaL, which indirectly modifies intracellular calcium levels as a result of sodium-calcium exchanger activity, may represent one of the pathways whereby a genetically determined reduction in FAM13B abundance increases risk of AF. Other sodium channel (SCN5A) gain of function mutations that increase sodium influx have also been associated with increased risk of cardiac arrhythmia. 16, 17 Our studies suggest that inhibition of INaL with new or available drugs, such as ranolazine, may reduce AF risk in patients carrying the FAM13B risk allele.
Expression of a FAM13B-GFP fusion protein in iCell cardiomyocytes demonstrated localization both in sarcomeres and on the plasma membrane ( Figure 5 ). The sarcomere staining overlaps or was adjacent to the Z-disc marker protein -actinin. This pattern may be due to FAM13B located on the Z-disk and/or the T-tubule, which connects the plasma membrane with deep invaginations near the Z-disk. Using the Gene Onloogy list for genes associated with the Z-disk in mice, we found the following other AF GWAS genes 2 that share this association: CASQ2, CFL2, FBXO32, KCNN2, MYH7, MYO18B, MYOZ1, SYNE2, SYNPO2L, and TTN Further understanding of the mechanism by which low expression of FAM13B, along with its binding partners and associated pathways, can predispose to AF susceptibility may illuminate targets for novel therapies. Thus, FAM13B is a potential target for drug development to prevent or treat AF. Representative INa traces and voltage-clamp protocol. A 100 ms prepulse to -120 mV was used from a holding potential of -60 mV. Depolarizing voltage steps from -80 to +70 mV were applied in 10 mV increments. B. Summary INa-V plot for scramble (n=20) vs. FAM13B knockdown (n=23) recordings. C. Inactivation protocol and representative INa traces. As in A, resting potential was -60 mV, with a 100 ms pre-pulse used to partially recover channels from inactivation, using pre-pulse potentials from -140 to -50 mV in 10 mV steps. INa was recorded with a step to -30 mV. D. INa currents were normalized to those recorded at -140 mV (I/Imax). A Boltzmann function was used to fit the half-inactivation potential (V1/2). A subset of the cells in B were characterized (scramble n=9, knockdown n=7). E. Slowly inactivating INa (INaL) was recorded using a 2s ramp clamp protocol from -140 to +50 mV (90 mV/second). Representative current traces normalized to cell capacitance are shown over the potential range -80 to -30 mV for a scramble (black) and FAM13B knockdown (red) cardiomyocyte. The baseline subtracted peak negative amplitude of the current recorded in this range was used as a measure of INaL. F. A subset of the cells in B were evaluated using the protocol in F. The percent of INaL to peak INa is plotted from scramble (n=11) vs. FAM13B knockdown (n=13) cells. 
